moneyheap
DRUG · Analysis updated Nov 3, 2026, 5:01 PM ET
Why is Bright Minds Biosciences Inc. (DRUG) stock moving?
DRUG fell about 52% on Nov 2, from $54.98 to a $26.20 close, on 23,471 trades. That is roughly 10 times the recent daily activity, and the intraday low was $18.90. The catalyst was an FDA partial clinical hold on the planned US Phase 2 BMB-101 trial in DEE. The FDA cited mouse toxicity and insufficient pharmacokinetic and juvenile toxicity data for pediatric enrollment. Management says the hold covers only that planned trial and not other ongoing studies. BTIG kept its Buy rating but cut its target to $37 from $147. It said the absence seizure franchise is still central to the thesis. The hold raises regulatory and pediatric-safety questions and may delay the DEE program. Shareholder-investigation notices add headline noise. The stock now trades well below its prior $47–55 range, with that range as overhead resistance and the $18.90 intraday low as support. Volatility is very high, and the stock may be repriced further as the hold's scope and the company's response become clearer.
News behind the analysis
- Bright Minds stock plunges as FDA halts epilepsy trialShares fell as much as 52% on Nov 2 after the FDA placed the planned Phase 2 BMB-101 trial in developmental and epileptic encephalopathies (DEE) on partial clinical hold. The FDA cited toxicity in mice and inadequate pharmacokinetic and juvenile toxicity data to support pediatric enrollment.
- Partial hold of Bright Minds' DEE drug sends shares plummetingBioWorld reports the stock lost more than half its value on Nov 2 after the partial hold on the planned BMB-101 Phase 2 DEE study.
- Bright Minds shares fall as BTIG cuts price target on clinical holdBTIG cut its price target to $37 from $147 and kept a Buy rating. It sees the hold as reflecting an incomplete clinical package for pediatric use, and says the absence seizure franchise remains central to the thesis.
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga lists DRUG among the biggest health care losers on Monday, down about 60% intraday to $22.09. The market cap was about $539 million at the time of the report.
- DRUG SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Bright Minds BiosciencesA law-firm-style notice says it is investigating possible securities claims tied to the sell-off after the partial clinical hold. This is an investigation, not a filed finding.
- Bright Minds Biosciences (DRUG) Stock Analysis - Simply Wall StThe profile describes positive Phase 2 data for BMB-101 in drug-resistant epilepsies. Median seizure reductions were reported at 73.1% in absence epilepsy and 63.3% in DEE cohorts.
- Bright Minds Biosciences Inc Ordinary Shares (DRUG) - MorningstarDRUG closed at $54.98 on Oct 30, before the hold news, and pre-open indications were near $30. The 52-week range is $47.23–$123.75, and the market cap was about $542M.